Transkaryotic plans hemophilia gene therapy trial in 1997 -- IPO prospectus.
Executive Summary
TRANSKARYOTIC HEMOPHILIA A GENE THERAPY SLATED FOR CLINICAL TRIALS IN 1997, the Cambridge, Mass.-based firm states in a recent prospectus for an initial public offering. Transkaryotic Therapies is developing a gene therapy product for "production and delivery of coagulation Factor VIII" in hemophilia A patients into clinical trials in 1997. The company has a nonexclusive license to Genetics Institute patents covering non-viral gene therapy with Factor VIII.